- Home
- CMA vs EXAS Comparison
CMA vs EXAS Comparison
Compare CMA & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- EXAS
- Stock Information
- Founded
- CMA 1849
- EXAS 1995
- Country
- CMA United States
- EXAS United States
- Employees
- CMA N/A
- EXAS N/A
- Industry
- CMA Major Banks
- EXAS Medical Specialities
- Sector
- CMA Finance
- EXAS Health Care
- Exchange
- CMA Nasdaq
- EXAS Nasdaq
- Market Cap
- CMA 7.7B
- EXAS 8.6B
- IPO Year
- CMA N/A
- EXAS N/A
- Fundamental
- Price
- CMA $69.52
- EXAS $47.47
- Analyst Decision
- CMA Hold
- EXAS Strong Buy
- Analyst Count
- CMA 21
- EXAS 22
- Target Price
- CMA $63.65
- EXAS $66.43
- AVG Volume (30 Days)
- CMA 1.8M
- EXAS 4.0M
- Earning Date
- CMA 07-18-2025
- EXAS 08-06-2025
- Dividend Yield
- CMA 4.24%
- EXAS N/A
- EPS Growth
- CMA 15.05
- EXAS N/A
- EPS
- CMA 5.21
- EXAS N/A
- Revenue
- CMA $3,215,000,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- CMA $6.73
- EXAS $14.61
- Revenue Next Year
- CMA $3.02
- EXAS $12.71
- P/E Ratio
- CMA $12.85
- EXAS N/A
- Revenue Growth
- CMA N/A
- EXAS 12.55
- 52 Week Low
- CMA $48.12
- EXAS $38.81
- 52 Week High
- CMA $73.45
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- CMA 62.22
- EXAS 52.00
- Support Level
- CMA $66.64
- EXAS $44.90
- Resistance Level
- CMA $68.26
- EXAS $46.26
- Average True Range (ATR)
- CMA 1.51
- EXAS 1.88
- MACD
- CMA -0.18
- EXAS 0.61
- Stochastic Oscillator
- CMA 85.71
- EXAS 94.03
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.